Abstract
Viruses belonging to the Flaviviridae family cause clinically significant diseases in humans and animals. This family includes three genera: Pestivirus [including bovine viral diarrhea virus (BVDV)], Flavivirus [including yellow fever virus (YFV), dengue virus, and West Nile virus (WNV)], and Hepacivirus [including hepatitis C virus (HCV)]. BVDV is responsible for major losses in cattle, causing a range of clinical manifestations, and is also a problematic contaminant in the laboratory. Noncytopathic BVDV infection can remain unnoticed and infect laboratory cell lines through its presence in contaminated bovine serum used in cell culture. BVDV is considered to be a valuable surrogate virus model for identifying and characterizing antiviral agents to be used against HCV. In some aspects of viral replication, BVDV is more advantageous than the currently used HCV replicon systems. In this review, we report the design, synthesis, and activity against BVDV of a series of compounds assayed until now.
Keywords: BVDV, HCV, Antiviral agents, Structure-activity relationship, Nucleosidic compounds, Non-nucleosidic compounds
Current Medicinal Chemistry
Title: What is Known About the Antiviral Agents Active Against Bovine Viral Diarrhea Virus (BVDV)?
Volume: 17 Issue: 26
Author(s): L.M. Finkielsztein, G.Y. Moltrasio, M.E. Caputto, E.F. Castro, L.V. Cavallaro and A.G. Moglioni
Affiliation:
Keywords: BVDV, HCV, Antiviral agents, Structure-activity relationship, Nucleosidic compounds, Non-nucleosidic compounds
Abstract: Viruses belonging to the Flaviviridae family cause clinically significant diseases in humans and animals. This family includes three genera: Pestivirus [including bovine viral diarrhea virus (BVDV)], Flavivirus [including yellow fever virus (YFV), dengue virus, and West Nile virus (WNV)], and Hepacivirus [including hepatitis C virus (HCV)]. BVDV is responsible for major losses in cattle, causing a range of clinical manifestations, and is also a problematic contaminant in the laboratory. Noncytopathic BVDV infection can remain unnoticed and infect laboratory cell lines through its presence in contaminated bovine serum used in cell culture. BVDV is considered to be a valuable surrogate virus model for identifying and characterizing antiviral agents to be used against HCV. In some aspects of viral replication, BVDV is more advantageous than the currently used HCV replicon systems. In this review, we report the design, synthesis, and activity against BVDV of a series of compounds assayed until now.
Export Options
About this article
Cite this article as:
Finkielsztein L.M., Moltrasio G.Y., Caputto M.E., Castro E.F., Cavallaro L.V. and Moglioni A.G., What is Known About the Antiviral Agents Active Against Bovine Viral Diarrhea Virus (BVDV)?, Current Medicinal Chemistry 2010; 17 (26) . https://dx.doi.org/10.2174/092986710792065036
DOI https://dx.doi.org/10.2174/092986710792065036 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Recent Advances in Discovering the Role of CCL5 in Metastatic Breast Cancer
Mini-Reviews in Medicinal Chemistry The Bioartificial Kidney in the Treatment of Acute Kidney Injury
Current Drug Targets Computer-Aided Drug Design Applied to Secondary Metabolites as Anticancer Agents
Current Topics in Medicinal Chemistry Editorial [ Pharmacological Modulation of Liver Ischemia - Reperfusion Injury Executive Editors: G.K. Glantzounis, D.P. Mikhailidis, A.M. Seifalian and B.R. Davidson ]
Current Pharmaceutical Design Using Compound Similarity and Functional Domain Composition for Prediction of Drug-Target Interaction Networks
Medicinal Chemistry Coagonist of GLP-1 and Glucagon Receptor Ameliorates Development of Non-Alcoholic Fatty Liver Disease
Cardiovascular & Hematological Agents in Medicinal Chemistry Chronic Pancreatitis and the Development of Pancreatic Cancer
Endocrine, Metabolic & Immune Disorders - Drug Targets The Impact of Inflammatory Profile on Selenium Levels in Hemodialysis Patients
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Cytoprotection and Immunomodulation in Cancer Therapy
Current Medicinal Chemistry - Anti-Cancer Agents A New Method for a Quantitative Determination of Piroxicam in Pharmaceutical Formulations Using FT-IR Spectrometry
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Tryptophan Catabolism in IDO+ Plasmacytoid Dendritic Cells
Current Drug Metabolism Psychosocial Stress, Emotions and Cytokine-Related Disorders
Recent Patents on Inflammation & Allergy Drug Discovery Integrins: Novel Therapeutic Targets for Cardiovascular Diseases
Cardiovascular & Hematological Agents in Medicinal Chemistry Editorial [Hot Topic: New Avenues of Research on Multiple Sclerosis from the Perspective of Chronic Cerebrospinal Venous Insufficiency Paradigm (Guest Editor: Marian Simka)]
Reviews on Recent Clinical Trials Mechanism of Cardiac Pathogenesis and Cardiotoxicity of Anti- COVID-19 Drugs
Coronaviruses Combined Angiogenic and Osteogenic Factor Delivery for Bone Regenerative Engineering
Current Pharmaceutical Design Challenges in Managing Amniotic Fluid Embolism: An Up-to-Date Perspective on Diagnostic Testing with Focus on Novel Biomarkers and Avenues for Future Research
Current Pharmaceutical Biotechnology Novel Targeting of Apoptosis Pathways for Prostate Cancer Therapy
Current Cancer Drug Targets Phospholipid Transfer Protein in Diabetes, Metabolic Syndrome and Obesity
Cardiovascular & Hematological Disorders-Drug Targets Animal Models Used for the Evaluation of Antiretroviral Therapies
Current HIV Research